The global drug screening market is projected to reach USD 20.86 billion by 2031, growing at a CAGR of 16.16%. Chromatography and mass spectrometry technologies dominated with 44.77% market share in 2025. Asia-Pacific is the fastest-growing region, driven by expanding healthcare infrastructure and workplace safety initiatives. Market growth is fueled by increasing adoption across workplaces, healthcare settings, and law enforcement, alongside technological advancements in point-of-care testing and rapid detection devices.

The global ELISpot & FluoroSpot assay market is projected to grow at a CAGR of 7.1% from 2025 to 2031, driven by increasing adoption of immunology research techniques, personalized immune therapies, and advanced diagnostic assays. Key growth areas include reagent products, pharmaceutical & biotechnology firms, and the APAC region. Major trends include automation, multiplexing capabilities, and expanding applications in clinical diagnostics, vaccine development, and immuno-oncology.

The global molecular diagnostics market is projected to reach USD 33.51 billion by 2031, growing at a CAGR of 10.43% from 2026 to 2031. Growth is driven by increasing adoption of precision medicine, advancements in genomic testing technologies, and rising prevalence of infectious and chronic diseases. North America leads the market while Asia-Pacific is expected to be the fastest-growing region.

The global microplate systems market was valued at USD 1.42 billion in 2025 and is projected to reach USD 2.88 billion by 2035, growing at a CAGR of 10.7%. Growth is driven by increased R&D spending in pharmaceuticals, rising demand for high-throughput screening in drug discovery, and innovations in multimode detection systems and automation. Key players include Thermo Fisher Scientific, Danaher Corporation, Agilent Technologies, PerkinElmer, and Bio-Rad Laboratories.

The global chromatography market is projected to grow from USD 10.03 billion in 2025 to USD 13.69 billion by 2031 at a CAGR of 5.32%, driven by expanding R&D in pharma/biotech and strict food safety regulations. However, high capital costs limit adoption among smaller entities. Emerging trends include green chromatography and AI-powered method optimization.

The global microarrays market is projected to grow from USD 6.16 billion in 2025 to USD 10.72 billion by 2033, at a CAGR of 7.24%. Growth is driven by increasing adoption of genomics and proteomics research, drug discovery applications, and disease diagnostics. North America dominates with 43% market share, while Asia Pacific emerges as the fastest-growing region with a 9.54% CAGR.

The global next-generation sequencing (NGS) market is expected to grow from USD 14.25 billion in 2025 to USD 103.24 billion by 2035, at a CAGR of 21.9%. North America currently dominates with 50% market share, while Asia Pacific is the fastest-growing region. Oncology is the leading application segment, and consumables represent the largest product category. Key industry players are advancing NGS technology through strategic partnerships and innovative platforms.

German life sciences company Qiagen is exploring strategic options including a potential sale, with renewed takeover interest from multiple U.S.-based strategic buyers. The company has engaged advisers as its supervisory board evaluates preliminary approaches. CEO Thierry Bernard's announced departure is seen as removing a key obstacle to a deal. Qiagen has attracted acquisition interest multiple times in recent years, including failed attempts from Thermo Fisher Scientific (2020, ~$12 billion), BioMérieux (2021), and Bio-Rad Laboratories (2022).

The global antibody optimization service market is projected to grow from USD 1.36 billion in 2024 to USD 2.87 billion by 2033, with a CAGR of 8.81%. Growth is driven by rising prevalence of complex diseases, increased R&D investments in biologics, and advancements in computational modeling and protein engineering technologies.

The global custom antibody market is projected to grow from USD 608.75 million in 2025 to USD 1,297.65 million by 2033, at a CAGR of 9.98%. Growth is driven by increasing demand for precision medicine, targeted therapies, advancements in antibody engineering, and rising investments in biopharmaceutical R&D. However, high development costs and technical challenges may hinder market expansion.

The global autism spectrum disorder diagnostics market is projected to grow from $27.38 billion in 2024 to $43.36 billion by 2034, with a CAGR of 4.7%. Key growth drivers include increasing healthcare expenditure, R&D investments, and government initiatives. The autistic disorder segment will dominate at 52.82% market share, while early intervention services and online pharmacies emerge as fastest-growing segments. Major players include LabCorp, Illumina, and Bio-Rad Laboratories, with Asia Pacific and Western Europe expected to lead regional growth.

The global IVD diagnostic molecule raw enzymes market is projected to grow from USD 2.39 billion in 2024 to USD 4.73 billion by 2034, with a 7.13% CAGR. Key growth drivers include increasing chronic diseases, technological advancements in molecular diagnostics, and rising demand for precision medicine.